Pharma BD Deal Intelligence
Roche pays a low upfront for payload chemistry outside the crowded TOP1 class
Full analysis, sources & comparables →DualityBio (Duality Biologics) granted Genentech, a member of the Roche Group, an exclusive worldwide license to develop and commercialise next-generation antibody-drug conjugates built on DualityBio's proprietary DUPAC (DualityBio Unique Payload Antibody Conjugate) novel-payload platform. DualityBio will generate and develop ADCs against Genentech-defined oncology targets and lead discovery and early global clinical development; Genentech assumes sole responsibility for further clinical development and commercialisation after Phase 1a. DualityBio receives a $45 million upfront payment and is eligible for more than $1 billion in aggregate development, regulatory and commercial milestone payments across all programs, plus tiered royalties on annual net sales. DUPAC is one of DualityBio's four proprietary ADC technology platforms and comprises multiple payloads with novel mechanisms of action designed to address resistance to the payload classes underlying currently approved ADCs. The agreement is Genentech's second Asia-Pacific licensing transaction announced within a week.
Roche pays a low upfront for payload chemistry outside the crowded TOP1 class
Assessment window: 5yr post-close.
Note: this deal's 5-year assessment window closes ~2031; the outcome grade above is a projected assessment, not yet finalized.
Solid-tumour ADC development has converged on a narrow set of payload classes, dominated by topoisomerase I (TOP1) inhibitors such as deruxtecan and SN-38, alongside older anti-tubulin payloads. Peer-reviewed 2026 reviews identify this concentration as a structural liability: limited mechanistic diversity drives cross-resistance, because target-specific mutations confer resistance to all agents sharing that target while leaving ADCs with orthogonal payload mechanisms unaffected. A TOP1 E418K mutation emerging after sacituzumab govitecan treatment is a documented example, conferring resistance to SN-38 and probably to other TOP1 inhibitors. Resistance is compounded by tumour heterogeneity, linker instability and off-target binding. The field's response is payload diversification - repurposing legacy antifolates and nucleoside analogues, and dual-payload constructs pairing mechanistically distinct cytotoxins.
Genentech is buying mechanistic diversity, not a target. The DUPAC platform supplies payload classes outside the TOP1/tubulin duopoly, which is the specific gap that limits ADC durability today. Structurally the deal is unusually cheap for Roche: $45M upfront against more than $1B in milestones leaves nearly all value contingent, and DualityBio carries discovery and early clinical development through Phase 1a before Genentech takes over. It is the second Asia-Pacific licensing transaction Genentech announced within a week, consistent with a pattern of sourcing differentiated chemistry from Chinese biotech at low upfronts.
DualityBio granted Genentech an exclusive worldwide licence to collaboration ADCs built on its DUPAC novel-payload platform against Genentech-defined oncology targets, for $45M upfront plus more than $1B in aggregate development, regulatory and commercial milestones and tiered royalties on net sales. DualityBio leads discovery and early global clinical development; Genentech assumes sole responsibility after Phase 1a.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Genentech, Inc. (Roche Group) / Duality Biologics (Suzhou) Co. Ltd. (this deal) | 2026 | $1.0B | 100 |
| Genentech, Inc. (Roche Group) / Hanmi Pharmaceutical Co. Ltd. | 2026 | $2.3B | 100 |
| Genentech, Inc. (Roche Group) / Tanox Inc. | 2006 | $919M | 80 |
| Genentech, Inc. (Roche Group) / Astex Pharmaceuticals | 2026 | $490M | 58 |
| Genentech, Inc. (Roche Group) / Affimed N.V. | 2018 | $5.1B | — |
| Genentech, Inc. (Roche Group) / Hanmi Pharmaceutical Co. Ltd. | 2016 | $910M | — |
| Genentech, Inc. (Roche Group) / Regor Pharmaceuticals Inc. | 2024 | $850M | — |